Clinical Trial Update: p53 Synthetic Long Peptides Vaccine With Cyclophosphamide for Ovarian Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of a p53 synthetic long peptide vaccine with cyclophosphamide for ovarian cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• p53 Synthetic Long Peptides Vaccine (p53 synthetic long peptide vaccine)

Snippet

Sponsor: University Medical Center Groningen | Conditions: Ovarian Cancer | Phase 2 | Status: COMPLETED